This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $2,156,262.00 to Case Western Reserve University's Office of Research Administration Division (doing business as University Hospitals of Cleveland) to conduct research on the role of N6-methyladenosine (m6A) RNA modification dysregulation in the pathogenesis of Alzheimer's disease. The research aims to determine how reduced expression of the m6A methyltransferase enzyme METTL3 modulates the expression of mitochondrial regulators and contributes to mitochondrial dysfunction in Alzheimer's disease. The project will utilize novel animal models to further investigate the therapeutic potential of restoring METTL3-mediated m6A signaling for addressing Alzheimer's-related deficits. The award period runs from September 1, 2023 to August 31, 2026.
Generated 8/13/24, 5:21 AM